VivoSim Labs (VIVS) Change in Accured Expenses (2010 - 2026)
VivoSim Labs (VIVS) posted Change in Accured Expenses of -$243000.0 for Q2 2026, down 249.08% on a QoQ basis from $163000.0 in Q1 2026, and up 51.3% year-over-year from -$160605.3 in Q2 2025.
Analysis
VivoSim Labs (VIVS) Change in Accured Expenses (2010 - 2026) Analysis & Trends
VivoSim Labs has reported Change in Accured Expenses for 17 years, with the latest figure at -$243000.0 in Q2 2026.
- On a quarterly basis, Change in Accured Expenses rose 51.3% year-over-year to -$243000.0 in Q2 2026; TTM through Jun 2026 was $11000.0, a 97.97% decrease from a year earlier, with the FY2026 full-year figure at -$245000.0, down 134.17% from the prior year.
- Change in Accured Expenses was -$243000.0 for Q2 2026 at VivoSim Labs, down from $163000.0 in the prior quarter.
- The five-year high for Change in Accured Expenses was $2.2 million in Q1 2023, with the low at -$2.1 million in Q2 2023.
- Average Change in Accured Expenses over 5 years is $1764.7, with a median of $47000.0 recorded in 2025.
- The sharpest annual moves came in 2022 and 2023: Change in Accured Expenses tumbled 2086.36% in 2022, then jumped 603.89% in 2023.
- Over 5 years, Change in Accured Expenses stood at $184000.0 in 2022, then tumbled by 66.85% to $61000.0 in 2023, then surged by 480.33% to $354000.0 in 2024, then tumbled by 86.72% to $47000.0 in 2025, then slumped by 617.02% to -$243000.0 in 2026.
- The last three Change in Accured Expenses figures came in at -$243000.0 (Q2 2026), $163000.0 (Q1 2026), and $47000.0 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Iqvia Holdings | 43.87 Bn | 41.92 Bn | 1.44 Bn | - |
| 2 | Medpace Holdings | 17.09 Bn | 16.59 Bn | 201.64 Mn | 45.02 Mn |
| 3 | Charles River Laboratories International | 13.27 Bn | 13.12 Bn | 452.07 Mn | 18.90 Mn |
| 4 | Icon | 12.57 Bn | 11.64 Bn | 479.29 Mn | - |
| 5 | Fortrea Holdings | 1.90 Bn | 1.73 Bn | 139.20 Mn | 25.10 Mn |
| 6 | Evotec SE | 568.89 Mn | 143.02 Mn | - | - |
| 7 | Ginkgo Bioworks Holdings | 502.68 Mn | 418.15 Mn | 18.44 Mn | 3.94 Mn |
| 8 | Champions Oncology | 73.77 Mn | 69.94 Mn | 7.70 Mn | 83,000.00 |
| 9 | MindWalk Holdings | 63.53 Mn | 58.06 Mn | 1.61 Mn | - |
| 10 | VivoSim Labs | 1.21 Mn | 1.21 Mn | - | -243,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -243,000.00 |
| Mar 31, 2026 | 163,000.00 |
| Dec 31, 2025 | 47,000.00 |
| Sep 30, 2025 | 44,000.00 |
| Jun 30, 2025 | -499,000.00 |
| Mar 31, 2025 | 211,000.00 |
| Dec 31, 2024 | 354,000.00 |
| Sep 30, 2024 | 475,000.00 |
| Jun 30, 2024 | -323,000.00 |
| Dec 31, 2023 | 61,000.00 |
| Sep 30, 2023 | -121,000.00 |
| Jun 30, 2023 | -2.06 Mn |
| Mar 31, 2023 | 2.20 Mn |
| Dec 31, 2022 | 184,000.00 |
| Sep 30, 2022 | -208,000.00 |
| Jun 30, 2022 | 181,000.00 |
| Mar 31, 2022 | -437,000.00 |
| Dec 31, 2021 | 209,000.00 |
| Sep 30, 2021 | 330,000.00 |
| Jun 30, 2021 | -53,000.00 |